NCT00356005

Azithromycin Combination Therapy for the Treatment of Uncomplicated Falciparum Malaria in Bangladesh

Azithromycin Combination Therapy for the Treatment of Uncomplicated Falciparum Malaria in Bangladesh: An Open Label Randomized Controlled Trial

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 228 (actual)
• Sponsor: Medical University of Vienna · Academic / Other
• Sex: All
• Age: 8 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate the efficacy of azithromycin combination therapy with artesunate for the treatment of uncomplicated falciparum malaria in Bangladesh.

Detailed description

In view of spreading antimalarial drug resistance there is an urgent need for new combination treatments for a disease that kills more than one million people every year. Azithromycin is a macrolide antibiotic that is particularly attractive due to its safety in children and experience with use in pregnancy. Recent trials suggest that azithromycin has a strong potential as an antimalarial. The purpose of this study is to investigate the efficacy of azithromycin combination therapy for the treatment of uncomplicated falciparum malaria in Bangladesh.

Conditions

• Uncomplicated Falciparum Malaria

Interventions

Type	Name	Description
DRUG	azithromycin plus artesunate
DRUG	Artesunate

Timeline

• Start date: 2006-08-01
• Primary completion: 2007-08-01
• First posted: 2006-07-25
• Last updated: 2012-11-01

Locations

1 site across 1 country: Bangladesh